
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed is a promising clinical-stage biotechnology company with a potential game-changing product candidate, Neflamapimod, that targets age-related neurologic disorders. At the Alzheimer's Association International Conference, the company presented data on treatment effects and pharmacokinetic/pharmacodynamic relationships that show Neflamapimod's potential to slow disease progression, improve biomarkers, and mitigate brain atrophy in dementia with Lewy bodies (DLB). Despite initial challenges in the Phase 2b trial due to patients with Alzheimer's co-pathology and low plasma concentrations, a pivotal trial is being prepared with FDA alignment and potential partnership in place, and further clinical studies in other indications may drive significant upside for the company's valuation.
Bears say
CervoMed is facing risks in initiating its Phase 3 trial for neflamapimod in a timely manner, as well as generating positive data from this pivotal program for regulatory approval. Additionally, potential market uptake may be slow and there is also a risk of dilution in the future. The company also has a planned clinical trial for the treatment of amyotrophic lateral sclerosis, which is slated to start by the end of this year and may provide a potential growth opportunity.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares